Q-omics provides the consensus-scored HLTF profile across patient tissues and cancer cell-line models. HLTF expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HLTF is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HLTF protein abundance shows 29,294 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, HNSC, and LSCC as cancer lineages where HLTF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLTF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLTF survival associations across molecular data types. HLTF RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLTF RNA expression–survival associations across cancer types. High HLTF expression shows unfavorable associations in KICH, LIHC, LUSC, COAD and SARC, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for HLTF RNA expression.
This table summarizes HLTF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 13. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HLTF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLTF shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher HLTF RNA expression in tumor versus normal tissue (log2 FC = +1.551, t-test p < 0.001).
This table shows molecular features associated with HLTF in patient tissues and cancer cell lines. In patient samples, HLTF shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HLTF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
